About Bolder Science

Our mission is to provide healthcare professionals with unbiased clinical research information, easily.

Currently, you can access the following clinical trials being conducted worldwide:

359,057 studies
in
219 countries
Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.
This website is for US healthcare professionals

Log In to Bolder Science

or

Don't have an account? Sign Up

Please enter your email address.

You will receive a link to create a new password via email.

Log In

Create an Account

or
(optional) ?

Welcome, !

Please complete the following 4 questions to ensure you receive the information that best suits your needs.

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

finding clinical trials in which to enroll my patients

Rarely Often

finding newly launched clinical trials (for all phases)

Rarely Often

updates on status changes for clinical trials

Rarely Often

pipeline molecules

Rarely Often

Drug Interventions

Enter up to 3 drug interventions you are currently interested in:

Clinical trial information and results are updated daily from ClinicalTrials.gov. The latest data update was conducted on 01/22/2021.

Is Periacetabular Osteotomy Superior to Progressive Resistance Training?

Clinicaltrials.gov identifier NCT03941171

Recruitment Status Recruiting

First Posted May 7, 2019

Last update posted July 31, 2019

Study Description

Brief summary:

The primary aim of this study is to examine if Periacetabular Osteotomy (PAO) followed by 4 months of usual care followed by 8 months of progressive resistance training (PRT) is superior to 12 months of a PRT intervention in patients with hip dysplasia eligible for PAO in terms of self-reported pain on the HAGOS questionnaire. Secondary aims are to investigate changes in patient-reported symptoms, physical function in daily living, physical function in sport and recreation, hip and/or groin-related quality of life, generic health status, functional performance, muscle strength, physical activity and adverse events between PAO followed by usual care+PRT compared to PRT only. We hypothesise that in patients with hip dysplasia, PAO followed by usual care+PRT, results in significantly less pain at 12 months follow-up, compared to PRT only.

  • Condition or Disease:Hip Dysplasia
  • Intervention/Treatment: Procedure: PAO
    Other: Usual care after PAO
    Other: PRT
  • Phase: N/A
Detailed Description

Group 1 (PAO+usual+PRT): PAO will be performed as the trans-sartorial approach or the anterior pelvic approach. Patients commence post-operative rehabilitation as usual and follow the rehabilitation program guided by a physiotherapist specialized in hip problems until 4 months after the operation. 4 months postoperative the patients complete usual care and continue with the same PRT intervention program as the PRT group, with 4 months of supervised sessions (see description below). Group 2 (PRT): The PRT group receives 4 months of supervised PRT 2 times per week. A physiotherapist or students will supervise all training sessions the first 4 weeks. The following 4 weeks, 6 out of 8 training sessions are supervised and from week 9-16, half of the training sessions (8 out of 16) are supervised. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of loaded squats, hip extension, hip flexion, and hip abduction. The absolute training load will be individually adjusted on a set-by-set basis, using the plus two principle (if the patient is able to perform two or more repetitions than required, the load is increased). Hip related pain levels up to 5 on the VAS is considered acceptable during exercise. The study is a multicentre randomised controlled and assessor blinded trial. Primary endpoint will be 12 months after initiation of surgical/non-surgical treatment. Secondary endpoints will be measured at 4 months after the start of the treatment (surgical/non-surgical). In addition, 5-year and 10-year follow-up with questionnaires is planned.

Study Design
  • Study Type: Interventional
  • Estimated Enrollment: 96 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Intervention Model Description: Randomized controlled trial
  • Masking: Single (Outcomes Assessor)
  • Primary Purpose: Treatment
  • Official Title: The Effect of PAO Followed by Progressive Resistance Training Versus Progressive Resistance Training in Patients With Hip Dysplasia. A Randomized Controlled Trial
  • Actual Study Start Date: July 2019
  • Estimated Primary Completion Date: July 2022
  • Estimated Study Completion Date: July 2023
Arms and interventions
Arm Intervention/treatment
Experimental: Group 1
PAO+usual+PRT
Procedure: PAO
PAO will be performed as the trans-sartorial approach or the anterior pelvic approach.

Other: Usual care after PAO
Patients commence post-operative rehabilitation as usual and follow the rehabilitation program guided by a physiotherapist specialized in hip problems until 4 months after the operation.

Other: PRT
4 months of partly supervised progressive resistance training 2 times per week. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of squats, hip extension, hip flexion, and hip abduction.
Active Comparator: Group 2
PRT
Other: PRT
4 months of partly supervised progressive resistance training 2 times per week. After these 4 months (16 weeks), patients receive a free membership to a fitness center near their home address and are encouraged to train on their own 2 times per week until 12 months follow-up with one supervised session per month. The PRT program involves 10-min of warm up followed by 50-min of bilateral resistance exercises including sets of squats, hip extension, hip flexion, and hip abduction.
Outcome Measures
  • Primary Outcome Measures: 1. Change in pain related to hip function, between baseline and 12 months follow-up [ Time Frame: Measured at baseline, 4 month follow-up and 12 month follow-up ]
    The pain subscale of the patient reported questionnaire Copenhagen Hip and Groin Outcome Score (HAGOS), were the total score ranges from 0 (worst) to 100 (best).
  • Secondary Outcome Measures: 1. Change in self-reported hip function [ Time Frame: Measured at baseline, 4 month follow-up and 12 month follow-up ]
    The subscales; Symptoms, Physical function in daily living, Physical function in Sport and Recreation, Participation in Physical Activities and hip and/or groin-related Quality of Life of the patient reported questionnaire Copenhagen Hip and Groin Outcome Score (HAGOS), where the total score ranges from 0 (worst) to 100 (best).
  • 2. Change in hip function [ Time Frame: Measured at baseline, 4 month follow-up and 12 month follow-up ]
    Single leg hop for distance is a test that measure functional performance requiring both strength, power and balance. The distance from start to landing is measured in cm. and height adjusted by dividing the distance of the hop with the height of the patient.
  • 3. Change in balance function [ Time Frame: Measured at baseline, 4 month follow-up and 12 month follow-up ]
    The Y balance test require strength, flexibility, neuromuscular control, stability, range of movement, balance and proprioception. These elements are tested and the maximal reach distance is recorded for each direction (anterior, posteromedial and posteroladeral). The composite reach is calculated and normalized to limb length for analysis of the overall performance on the test.
  • 4. Number of patients with adverse events and serious adverse events after PAO [ Time Frame: Reported within 12 months after surgery ]
    Adverse events: Haematoma Delayed wound closure Dysaethesia of lateral femoral cutaneous nerve Malpositioning; retroversion or insufficient reorientation. Insufficient reorientation (coverage) - optimal is CE angle 30-40 degrees. AI angle 0-10 degrees. Heterotopic ossifications (Brooker I and II) Urinary tract infections Infection not requiring surgical revision Serious adverse events: Avascular necrosis of the femoral head or acetabulum Nerve palsy Major bleeding (administration of more than 5 blood units intra- and postoperatively) Peroneal and femoral neurapraxia Deep vein thrombosis Pulmonary embolism Stress fracture of ischial bone and posterior column Intraarticular osteotomy Heterotopic ossifications (Brooker III and IV) Infection requiring surgical revision Loss of fixation/loss of reorientation Delayed or non-union of pubic, ischial or iliac bone
  • 5. Change in usage of painkillers [ Time Frame: Measured at baseline, 4 month follow-up and 12 month follow-up ]
    Usage of painkillers (yes/no), including type of painkillers (Paracetamol, NSAID, Morfin/opiods and/other type of medicine)
  • 6. Change in self-reported pain [ Time Frame: Measured at baseline, 4 month follow-up and 12 month follow-up ]
    Pain reported by the Visual Analogue Scale (VAS). A scale where pain is marked from 0-100, and 0 is no pain and 100 is worst imaginable pain.
  • 7. Change in hip awareness [ Time Frame: Measured at baseline, 4 month follow-up and 12 month follow-up ]
    Hip awareness is measured with the Forgotten Joint Score questionnaire (FJS), where each patient completes the 12 questions regarding awareness of their affected hip. Each question is answered with one of the following options; never, almost never, seldom, sometimes and mostly, corresponding to a score of 1-5. The sum of the scores will be converted into a score between 0-100. A high score will indicate lack of awareness and a low score will indicate great awareness of the affected hip.
  • 8. Change in muscle strength [ Time Frame: Measured at baseline, 4 month follow-up and 12 month follow-up ]
    Muscle strength in hip-abduction, hip-flexion and hip-extension is measured isometrically, with a dynamometer.
  • Other Outcome Measures: 1. Change in physical activity [ Time Frame: Measured at baseline and 12 month follow-up ]
    Tri-axial accelerometer
  • 2. Change in patient-reported health [ Time Frame: Measured at baseline, 4 month follow-up and 12 month follow-up ]
    Change in patient-reported health will be measured with the EuroQol Group 5-dimension patient-reported questionnaire (EQ-5D-5L), where each dimension has five response levels; ranging from no problems to extreme problems (level 1 to level 5). The scores will be combined, using one level from each dimension, ranging from 11111 (best health) to 55555 (worst health). The instrument also includes a visual analogue scale (VAS) where self-perceived health is scored on a 0 to 100 mm scale representing "the worst health you can imagine" and "the best health you can imagine".
Eligibility Criteria
  • Ages Eligible for Study: 18 to 40 Years (Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: Yes
Criteria

Inclusion Criteria:

1. Patients aged 18-40 years and diagnosed with hip dysplasia referred from primary care
to the Department of Orthopaedic Surgery at one of the two participating hospitals.

2. Considered eligible for PAO by a surgeon.

3. Radiographic verified hip dysplasia (CE-angle 10 degrees)
and clinical symptoms.

4. Range of motion: internal rotation >15 degrees, external rotation >15 degrees, hip
flexion >110 degrees.

5. Able to commute to training sessions.

Exclusion Criteria:

1. OA degree ≥2 on classification of Tönnis'.

2. CE-angle 25.

Contacts and Locations
Contacts

Contact: Lisa CU Reimer, MSc +45 26474080 lisareimer@clin.au.dk

Contact: Inger Mechlenburg, DMSc, PhD +45 21679062 inger.mechlenburg@clin.au.dk

Locations

Denmark, Midtjylland
Aarhus University Hospital
Aarhus

Norway
Oslo University Hospital
Oslo

Sponsors and Collaborators

University of Aarhus

Aarhus University Hospital

VIA University College

Investigators

Principal Investigator: Lisa CU Reimer, MSc Department of Orthopedic Surgery, Aarhus University Hospital, Denmark

Study Director: Inger Mechlenburg, DMSc, PhD Department of Clinical Medicine, Aarhus University, Denmark

Study Director: Ulrik Dalgas, MSc, PhD Department of Public Health - Sport, Aarhus University, Denmark

Study Director: Stig S Jakobsen, PhD Department of Orthopedic Surgery, Aarhus University Hospital, Denmark

Study Director: Kjeld Søballe, DMSc Department of Orthopedic Surgery, Aarhus University Hospital, Denmark

Study Director: Julie S Jacobsen, MSc Department of Physiotherapy & Research Centre in Health and Welfare Technology, VIA University College, Denmark

Study Director: Jan E Madsen, MD, PhD Department of Orthopedic Surgery, Oslo University Hospital, Norway

Study Director: Lars Nordsletten, PhD Division of Orthopaedic Surgery, Oslo University Hospital, Oslo; Faculty of Medicine, University of Oslo, Norway

Study Chair: Tone Bere, PT, PhD Department of Orthopedics, Oslo University Hospital Ullevaal, Norway

Study Director: May A Risberg, PhD Department of Orthopedics, Oslo University Hospital Ullevaal, Norway

More Information
  • Responsible Party: University of Aarhus
  • ClinicalTrials.gov Identifier: NCT03941171 History of Changes
  • Other Study ID Numbers: PreserveHIP
  • First Posted: May 7, 2019 Key Record Dates
  • Last Update Posted: July 31, 2019
  • Last Verified: April 2019
  • Individual Participant
    Data (IPD) Sharing
    Statement:
  • Plan to Share IPD: Yes
  • Plan Description: Aarhus University Hospital is responsible for handling all personal data provided by both sites in accordance to the Clinical Trial Agreement and the EU General Data Protection Regulation (GDPR).
  • Access Criteria: Oslo University Hospital agree that information directly related to the protocol and trial, including data, material, Intellectual Property and results generated from the trial shall be the property of Aarhus University Hospital, and shall be treated in strict confidence, and shall not be disclosed to any third party, or use for its benefit or the benefit of any third party, without the prior written consent of Aarhus University Hospital, except for data that is (i) publicly known or available from other sources who are not under a confidentially obligation to the other party; (li) has been made available by the other party without confidentiality obligation; or (iii) is independently developed or otherwise already known by or available to the other party without a confidentiality obligation; or (iv) is already required disclosed by law.
  • Studies a U.S. FDA-regulated Drug Product: No
  • Studies a U.S. FDA-regulated Device Product: No
  • Keywords provided by University of Aarhus: PAO
    Periacetabular Osteotomy
    Progressive resistance training
  • Additional relevant MeSH terms: Hip Dislocation Hip Dislocation, Congenital